Coloplast (COLO) AGM 2025 summary

Opening remarks and agenda

• Board and management introduced, including interim CEO and new board candidates.

• AGM confirmed as lawfully convened with 87.14% of votes represented.

• Meeting agenda included board report, annual report approval, profit allocation, remuneration, proposals, board and auditor elections, and other business.

• Agenda included financial report, profit distribution, remuneration, board elections, and strategy update.

Financial performance review

• Organic revenue growth reached 7%, with DKK 27.9 billion in revenue and a 28% profit margin before special items.

• Net profit for the year was DKK 3,636m, with free cash flow at DKK 5,394m.

• Return on invested capital after tax was 15%; free cash flow DKK 5.4 billion.

• Share price declined from 875 DKK (Sep 2024) to 543 DKK (Dec 2025).

• Financial outlook for 2025-2026 expects 7% organic growth and 16% return on invested capital.

Board and executive committee updates

• Leadership transition underway: Lars Rasmussen as interim CEO, search for new CEO ongoing.

• Board members Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen, Marianne Wiinholt, and Niels Peter Louis-Hansen proposed for re-election; Niels B. Christiansen proposed as new member, expected to become chairman by next AGM.

• Board focused on continuity, leadership pipeline, and annual evaluation of competencies.